Search - tctmd.com

Displaying 61 - 80 of 1171

Sort: Relevancy | Date

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

News Daily News

Sudden Deaths After Acute MI Have Dropped, but Early Weeks Remain Risky

Yael L. Maxwell

August 08, 2024

News Daily News

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Yael L. Maxwell

June 26, 2024

News Daily News

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

Yael L. Maxwell

June 20, 2024

News Daily News

Risk of Death Remains Low a Decade After Primary PCI for STEMI

Caitlin E. Cox

June 18, 2024

News Daily News

AHA Celebrates a Century by Looking Back, and Forward

Shelley Wood

June 10, 2024

News Daily News

Excess ApoB Linked to Increased MI, ASCVD Risk in Adults

Michael O'Riordan

June 04, 2024

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

L.A. McKeown

June 01, 2024

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

News Daily News

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

Michael O'Riordan

May 02, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

Presentation ACC 2024

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Presenter: Gregg W Stone

April 07, 2024

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

News Conference News ACC 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Yael L. Maxwell

April 06, 2024

News Opinion CV Team Dispatch

April 2024 Dispatch for the CV Team

L.A. McKeown

April 01, 2024

News Daily News

Even Low Levels of ApoB and LDL Linked With CAD, Mortality: UK Biobank

Michael O'Riordan

January 23, 2024

News Daily News

No Benefit to P2Y12 Inhibitor Pretreatment in STEMI, Bern-PCI Data Confirm

Yael L. Maxwell

January 10, 2024

Advertisement

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Sudden Deaths After Acute MI Have Dropped, but Early Weeks Remain Risky

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

Risk of Death Remains Low a Decade After Primary PCI for STEMI

AHA Celebrates a Century by Looking Back, and Forward

Excess ApoB Linked to Increased MI, ASCVD Risk in Adults

June 2024 Dispatch for the CV Team

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

April 2024 Dispatch for the CV Team

Even Low Levels of ApoB and LDL Linked With CAD, Mortality: UK Biobank

No Benefit to P2Y12 Inhibitor Pretreatment in STEMI, Bern-PCI Data Confirm

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content